Zymeworks Inc Stock News

If you're willing to attempt a difficult balancing act in seeking out a discount and potentially imminent upside momentum at roughly the same time, these adventurous undervalued growth stocks could be

Growth stocks are often expensive in that they trade with high valuations like price-to-earnings (P/E) and price-to-sales (P/S) ratios. Yet, these high valuations might be justified if the company can

VANCOUVER, British Columbia, June 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced

Zymeworks Inc. (NASDAQ:ZYME ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Kenneth Galbraith - Chairman, Chief Executive Officer Neil Klompas - President, Chief Operati

VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced t

Heading into unchartered territory in the market, investors may take comfort in acquiring the most undervalued stocks. Primarily, the less-popular enterprises offer the advantage of being exactly that

Zymeworks has an enterprise value approaching zero, as milestone drug development payments were paid to the company in 2022. A significant pipeline, with partners helping to finance drug trials, is wo

Zymeworks Inc. (NASDAQ: ZYME) stock is up almost 5% after beating analysts' expectations for revenue and earnings in its March 7, 2023 earnings report. The clinical-stage biopharmaceutical company is

Zymeworks Inc. (NASDAQ:ZYME ) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Jack Spinks - Head of Investor Relations Chris Astle - Senior Vice President & Chief Financ

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 0.65% and 8.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zanidatamab passed the key test in December that led to partner Jazz's opt-in. HERIZON-BTC-01 results exceeded expectations with a much longer duration of response.

Zymeworks Inc. (ZYME) closed the most recent trading day at $8.57, making no change from the previous trading session.

VANCOUVER, British Columbia--( BUSINESS WIRE )--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management

Shares of Zymeworks Inc. ZYME, rallied 14% in premarket trading on Thursday after the company and Jazz Pharmaceuticals Inc. JAZZ, -0.58% said their experimental cancer drug had an overall survival rat

Two new Breakout Stocks for Week 3 with better than 10% short-term upside and two Dow 30 Picks. Average cumulative returns for 2023 are +21.37% YTD. This week 2 of 4 high-frequency breakout picks gain